The AVAC Advocacy Fellows Program is now recruiting its 13th class and is looking for the next cohort of emerging and mid-career advocates to explore what’s needed to address epidemics and progress global public health equity.
Want to help spread the word? Download our shareable social media tile.
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
This table is a work in progress, as this is an incredibly dynamic landscape. Over the past month, the scientific community has accelerated development of COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of resources available to track these developments.
In addition, a collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration and Treatment Action Group offers concise overviews and analyses of key research areas.